MTOR and Spinocerebellar ataxia type 3: Rapamycin a key modulator of the mammalian Target of Rapamycin (mTOR) pathway has shown significant promise and neuroprotection in Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3 [71, 72, 85].